Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/3/2022 | Outperform → Market Perform | William Blair | |
| 2/2/2022 | $16.00 → $6.00 | Hold | Chardan Capital |
| 12/23/2021 | $20.00 → $16.00 | Buy | Chardan Capital |
| 11/17/2021 | $24.00 → $8.00 | Overweight | Barclays |
| 11/16/2021 | $17.00 → $16.00 | Market Outperform | JMP Securities |
OAKLAND, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (NASDAQ:LOGC) ("ContextLogic," the "Company," "we" or "our") today reported its financial results for the quarter ended March 31, 2025. First-Quarter 2025 Financial Highlights Net Loss: Net loss was $4 million, compared to a net loss of $59 million in the first quarter of fiscal year 2024.As of March 31, 2025, the Company had $64 million in cash and cash equivalents, $158 million in marketable securities and $1 million in prepaid expenses and other current assets primarily made up of restricted cash. The Company had total liabilities of $3 million. ContextLogic will host a financial results conference call a
OAKLAND, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (NASDAQ:LOGC), ("ContextLogic" or the "Company") today announced it will report its first quarter 2025 financial results after the close of market on Friday, May 9, 2025. ContextLogic's CEO Rishi Bajaj and its Chairman Ted Goldthorpe will host a live conference call and webcast for shareholders, analysts and portfolio managers that afternoon at 5:00 PM ET / 2:00 PM PT. Information about the Company's financial results, including a link to the live webcast and replay will be made available on the Company's investor relations website at https://ir.contextlogicinc.com. The live conference call may be accessed by registering
OAKLAND, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (NASDAQ:LOGC) ("ContextLogic," the "Company," "we" or "our") today reported its financial results for the quarter and fiscal year ended December 31, 2024. Company Update During 2024, management took several significant steps in the evolution of the Company's business. These included, first, the sale of the Wish platform and its associated operations; second, streamlining the Company's operations; and most recently, on March 11, 2025, the Company announced the initial closing of the investment by BC Partners of $75 million in convertible preferred units in a subsidiary of ContextLogic. This investment, along
Strategic investment and capital commitment positions the Company to execute on its stated acquisition-led value maximization strategy; ContextLogic to have up to $300 million of investible cash Ted Goldthorpe, Head of BC Partners Credit, expected to be named Chairman of the Board OAKLAND, Calif. and NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (NASDAQ:LOGC), ("ContextLogic" or the "Company") and BC Partners, an alternative investment manager with c.€40 billion in assets under management, today announced that a fund advised by BC Partners Advisors L.P. will purchase up to $150 million of convertible preferred units (the "Preferred Units") of ContextLogic Holdings, L
LEXINGTON, Mass., March 4, 2022 /PRNewswire/ -- LogicBio® Therapeutics, Inc. (NASDAQ:LOGC), a clinical-stage genetic medicine company, today reported financial results for the year ended December 31, 2021, and provided business updates. "At LogicBio, we are continuing to advance our mission to safely deliver novel genetic medicines to people impacted by devastating, early onset diseases," said Frederic Chereau, president and chief executive officer of LogicBio. "We are pleased to report that the serious adverse event experienced by the fourth patient enrolled in our Phase 1/2 SUNRISE trial of LB-001 in pediatric patients with methylmalonic acidemia has resolved." Recent Business Update
LEXINGTON, Mass., May 19, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today announced the promotion of Daniel Gruskin, MD, as chief medical officer. Dr. Gruskin most recently served as senior vice president and head of clinical development. The Company also announced the appointment of Stephen Boyer, PhD, as vice president of regulatory and quality affairs, and Peter Pechan, PhD, as vice president of gene therapy, who will support progress in the Phase I/II SUNRISE clinical trial of LB-001, the Company's investi
10-Q - ContextLogic Inc. (0001822250) (Filer)
8-K - ContextLogic Inc. (0001822250) (Filer)
SCHEDULE 13G/A - ContextLogic Inc. (0001822250) (Subject)
4 - ContextLogic Inc. (0001822250) (Issuer)
4 - ContextLogic Inc. (0001822250) (Issuer)
4 - ContextLogic Inc. (0001822250) (Issuer)
OAKLAND, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (NASDAQ:LOGC) ("ContextLogic," the "Company," "we" or "our") today reported its financial results for the quarter ended March 31, 2025. First-Quarter 2025 Financial Highlights Net Loss: Net loss was $4 million, compared to a net loss of $59 million in the first quarter of fiscal year 2024.As of March 31, 2025, the Company had $64 million in cash and cash equivalents, $158 million in marketable securities and $1 million in prepaid expenses and other current assets primarily made up of restricted cash. The Company had total liabilities of $3 million. ContextLogic will host a financial results conference call a
OAKLAND, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (NASDAQ:LOGC), ("ContextLogic" or the "Company") today announced it will report its first quarter 2025 financial results after the close of market on Friday, May 9, 2025. ContextLogic's CEO Rishi Bajaj and its Chairman Ted Goldthorpe will host a live conference call and webcast for shareholders, analysts and portfolio managers that afternoon at 5:00 PM ET / 2:00 PM PT. Information about the Company's financial results, including a link to the live webcast and replay will be made available on the Company's investor relations website at https://ir.contextlogicinc.com. The live conference call may be accessed by registering
OAKLAND, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (NASDAQ:LOGC) ("ContextLogic," the "Company," "we" or "our") today reported its financial results for the quarter and fiscal year ended December 31, 2024. Company Update During 2024, management took several significant steps in the evolution of the Company's business. These included, first, the sale of the Wish platform and its associated operations; second, streamlining the Company's operations; and most recently, on March 11, 2025, the Company announced the initial closing of the investment by BC Partners of $75 million in convertible preferred units in a subsidiary of ContextLogic. This investment, along
William Blair downgraded LogicBio Therapeutics from Outperform to Market Perform
Chardan Capital reiterated coverage of LogicBio Therapeutics with a rating of Hold and set a new price target of $6.00 from $16.00 previously
Chardan Capital reiterated coverage of LogicBio Therapeutics with a rating of Buy and set a new price target of $16.00 from $20.00 previously
SC 13G/A - ContextLogic Inc. (0001822250) (Subject)
SC 13G/A - LogicBio Therapeutics, Inc. (0001664106) (Subject)
SC 13D/A - LogicBio Therapeutics, Inc. (0001664106) (Subject)